Any current/future new fundraising through debt or equity?

The transcript does not mention any current or planned fundraising through debt or equity. The company has ongoing capital expenditures (CAPEX) for expansions, such as Rs. 350 Cr+ Rs. 100 Cr for Unit-III and Rs. 1,000 Cr for Unit-IV, but no specific funding sources are discussed. There is no explicit indication of equity or debt issuance to fund these expansions in the provided discussion. The management focuses on organic growth and capacity utilization rather than discussing new fundraising rounds. Any future funding plans, if considered, were not disclosed in this transcript.

Any current/future capex/capital investment/strategic investment?

Unit-IV: Rs. 1,000 Cr CAPEX planned for greenfield expansion with ~400 KL custom synthesis and ~100-200 KL fermentation capacity, expected to be commissioned within 2 years (by FY27-FY28). Unit-III: Additional Rs. 100 Cr CAPEX to complete fermentation facilities by end of current year; limited further CAPEX expected afterward. Unit-II: CP 6 and CP 7 expansions (~130 KL capacity) recently commissioned with Rs. 350 Cr plus Rs. 100 Cr CAPEX done; generating revenue potential of ~Rs. 300 Cr. Focus on filling existing expanded capacities (Units II & III) before ramping up Unit-IV. Replaceme

Future growth expectations in sales/revenue/volumes?

Anthem Biosciences targets a compound annual growth rate (CAGR) of around 20% in revenue over the next several years, consistent with its past 10-15 years' performance. Recent approval of 4 new commercial molecules is expected to drive growth, though some may be in pre-launch phases affecting immediate supply volumes. Quarterly revenues may be lumpy due to fluctuating customer demand, but an overall upward trend is expected annually. Existing molecules are growing robustly, with customers managing inventories carefully, which may temporarily affect volumes but growth remains strong. Ex

Future growth expectations in earnings/operating earnings/profits/EPS?

Anthem Biosciences targets a revenue CAGR of approximately 20% over the next 5-10 years, consistent with its historical growth. Short-term quarterly growth may be lumpy, with some quarters showing exceptional performance and others moderate, but a clear upward trend is expected. Profit margins are anticipated to remain strong, with EBITDA margins aimed at the upper end of the 36%-37% range. The company expects growth from new commercial molecules launched recently, though ramp-up may take time as customers plan product launches. Expansion in capacities (Unit-III and Unit-IV) will drive future

Current/ Expected Orderbook/ Pending Orders?

Anthem Biosciences has observed a healthy inflow of new inquiries and RFPs, indicating a strong order book pipeline. The company mentions being ready with capacities (including Unit-III and upcoming Unit-IV) to service new RFPs over the next 2-3 years. While exact pending order numbers are not disclosed, management is enthused by the steady flow of new good customers and inquiries. The commissioning of Unit-III has already started generating revenues (~Rs. 55 Cr WIP), with plans to ramp this up to Rs. 100-150 Cr, supporting order execution. The upcoming Unit-IV, expected to be commissi

IN US

Sale is live|00:00:00left today

Anthem Biosciences LtdQ3 FY25Pharmaceuticals & Biotechnology

Anthem Biosciences Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹769P/E: 87.5Market Cap: ₹44.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→Anthem Biosciences targets a compound annual growth rate (CAGR) of around 20% in revenue over the next several years, consistent with its past 10-15 years' performance.
→Recent approval of 4 new commercial molecules is expected to drive growth, though some may be in pre-launch phases affecting immediate supply volumes.
→Quarterly revenues may be lumpy due to fluctuating customer demand, but an overall upward trend is expected annually.
→Existing molecules are growing robustly, with customers managing inventories carefully, which may temporarily affect volumes but growth remains strong.
→Expansion projects (Unit-III and Unit-IV) and new capacities (e.g., 130 kiloliters added recently, Unit-IV with 400 kiloliters planned) aim to support increased volumes and revenues.
→New product launches, including peptides and biologics, and collaborations with innovators are anticipated to contribute positively over the medium term.
→While short-term funding uncertainties exist in biotech markets, Anthem’s strong sales funnel and customer base mitigate concerns on demand.

Margin guidance

Category 3

→Anthem Biosciences targets a revenue CAGR of approximately 20% over the next 5-10 years, consistent with its historical growth.
→Short-term quarterly growth may be lumpy, with some quarters showing exceptional performance and others moderate, but a clear upward trend is expected.
→Profit margins are anticipated to remain strong, with EBITDA margins aimed at the upper end of the 36%-37% range.
→The company expects growth from new commercial molecules launched recently, though ramp-up may take time as customers plan product launches.
→Expansion in capacities (Unit-III and Unit-IV) will drive future revenue, with Unit-III already generating Rs. 55 Cr WIP and expected to contribute Rs. 100-150 Cr in the near term.
→Employee cost management and operational leverage are priorities to sustain margin expansion.
→Overall, a healthy increase in EBITDA, PBT, PAT, and EPS is expected, aligned with revenue growth targets.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript does not mention any current or planned fundraising through debt or equity.
→The company has ongoing capital expenditures (CAPEX) for expansions, such as Rs. 350 Cr+ Rs. 100 Cr for Unit-III and Rs. 1,000 Cr for Unit-IV, but no specific funding sources are discussed.
→There is no explicit indication of equity or debt issuance to fund these expansions in the provided discussion.
→The management focuses on organic growth and capacity utilization rather than discussing new fundraising rounds.
→Any future funding plans, if considered, were not disclosed in this transcript.

Order book

Yes

→Anthem Biosciences has observed a healthy inflow of new inquiries and RFPs, indicating a strong order book pipeline.
→The company mentions being ready with capacities (including Unit-III and upcoming Unit-IV) to service new RFPs over the next 2-3 years.
→While exact pending order numbers are not disclosed, management is enthused by the steady flow of new good customers and inquiries.
→The commissioning of Unit-III has already started generating revenues (~Rs. 55 Cr WIP), with plans to ramp this up to Rs. 100-150 Cr, supporting order execution.
→The upcoming Unit-IV, expected to be commissioned in about two years, will further enhance capacity to handle increased orders, reflecting confidence in sustained order inflows.
→Overall, Anthem expects consistent order growth to maintain around 20% CAGR over the next several years based on current trends.

Capex plans

Yes

→Unit-IV: Rs. 1,000 Cr CAPEX planned for greenfield expansion with ~400 KL custom synthesis and ~100-200 KL fermentation capacity, expected to be commissioned within 2 years (by FY27-FY28).
→Unit-III: Additional Rs. 100 Cr CAPEX to complete fermentation facilities by end of current year; limited further CAPEX expected afterward.
→Unit-II: CP 6 and CP 7 expansions (~130 KL capacity) recently commissioned with Rs. 350 Cr plus Rs. 100 Cr CAPEX done; generating revenue potential of ~Rs. 300 Cr.
→Focus on filling existing expanded capacities (Units II & III) before ramping up Unit-IV.
→Replacement CAPEX expected to be minor, mainly on repairs and maintenance.
→Continuous strategic investment in people training and capacity calibration aligned with revenue growth.

How does Anthem Biosciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Anthem Biosciences Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Anthem Biosciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio